Table 2. Summerized data received from the analysis of pooled serum samples from healthy individuals (C1-C7) and patients with prostate cancer (P1-P7) using methylation-sensitive high-resolution melt (MS-HRM) analysis, digital droplet PCR (ddPCR) alone, unbiased pre-amplification (UBPA)-ddPCR and optimized bias-based pre-amplification (OBBPA)-ddPCR.
| ID | ng of cfDNA | PSA (ng/ml) | Gleason score | MS-HRM | ddPCR alone <4.7 | UBPA-ddPCR <4.0 | OBBPA-ddPCR <1.3 |
|---|---|---|---|---|---|---|---|
| C1 | 640 | - | - | - | - | - | - |
| C2 | 320 | - | - | - | - | - | - |
| C3 | 920 | - | - | - | - | - | - |
| C4 | 152 | - | - | - | - | - | - |
| C5 | 320 | - | - | - | - | - | - |
| C6 | 340 | - | - | - | - | - | - |
| C7 | 400 | - | - | - | - | - | - |
| P1 | 2200 | 21,103 ± 6,510 | 10 | - | - | - | - |
| P2 | 560 | 730.0 ± 141.7 | 10 | - | - | - | - |
| P3 | 680 | 636.9 ± 350.8 | 10 | +++ | 15.5 | 13.2 | 97.0 |
| P4 | 640 | 85.7 ± 6.9 | 9 + 10 | - | - | - | 96.9 |
| P5 | 1240 | 25.5 ± 6.3 | 9 | - | - | - | 73.4 |
| P6 | 224 | 9.3 ± 2.2 | 7 | - | - | - | - |
| P7 | 840 | 8.2 ± 1.7 | 6 + 7 | + | - | - | 69.6 |
Amounts of isolated cell-free DNA (cfDNA) from 5.0 ml pooled serum samples, averaged PSA values of prostate cancer patients, Gleason scores and cutoff values together with fractional abundances observed by the different ddPCR methods are shown.